Licensing status

Publication and contact information


Brain cancer

Natural cytotoxicity triggering receptor 1
(NCR1; NKP46; CD335); natural killer p30 receptor (NKp30; NCR3; CD337)

Mouse and cell culture studies suggest inhibiting NCR1 or NCR3 could enhance oncolytic viral therapies to treat glioblastoma. In mice with human glioblastoma cells injected with the oncolytic herpes virus rQNestin34.5, depletion of NK cells increased tumor levels of rQNestin34.5 and survival compared with no NK cell depletion. In human glioblastoma cells, rQNestin34.5 increased levels of the NK cell receptors NCR1 and NCR3 compared with mock treatment. In the glioblastoma xenograft mice treated with rQNestin34.5, those transplanted with Ncr1-deficient NK cells showed greater survival than those transplanted with wild-type NK cells. Next steps include identifying NCR1 and NCR3 ligands that are unregulated.

SciBX 5(48); doi:10.1038/scibx.2012.1252
Published online Dec. 13, 2012

rQNestin34.5 patented by Massachusetts General Hospital; available for licensing

Alvarez-Breckenridge, C.A. et al. Nat. Med.; published online Nov. 25, 2012;
Contact: E. Antonio Chiocca, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Mass.

Contact: Michael A. Caligiuri, The Ohio State University, Columbus, Ohio